Child Health
Our growth hormone deficiency guide covers the signs of GHD and how doctors confirm it, and our guide on when to worry about a child's height covers the red flags that lead to a growth workup. This piece picks up where those leave off: what growth hormone therapy actually involves, which children it's approved for, how much height it adds, what risks doctors watch for, and why experts treat a true deficiency very differently from a child who is simply short.
How Much Adult Height Does GH Add in Idiopathic Short Stature?
Average gains reported for healthy short children without GH deficiency
Who Growth Hormone Therapy Is Approved For
In GH deficiency, treatment restores a hormone the body isn't making enough of. Experts consider this uncontroversial, and the benefits include body composition and metabolic health, not just height.
For most other approved uses, the child isn't GH deficient and treatment is given to increase growth. Here the goal is height, and the trade-offs need more careful weighing.
Recombinant growth hormone was first approved by the U.S. Food and Drug Administration (FDA) for children with GH deficiency in 1985. Over the next two decades, approvals expanded to chronic kidney insufficiency (1993), Turner syndrome (1996), Prader-Willi syndrome (2000), children born small for gestational age who don't catch up (2001), idiopathic short stature (2003), SHOX gene deficiency (2007), and Noonan syndrome (2008). Every pediatric approval was originally based on height and growth, though health benefits beyond height were later recognized for GH deficiency and Prader-Willi syndrome.
Being short, on its own, is not a reason for treatment. A full evaluation comes first, because common causes of short stature such as familial short stature and constitutional growth delay are normal variants that usually need monitoring rather than medication. Idiopathic short stature is a diagnosis given only after a pediatric endocrinologist has found no other cause, including GH testing results that don't indicate a deficiency.
What Treatment Actually Involves
Growth hormone can't be taken by mouth. It's injected under the skin, usually at home by a parent or, as children get older, by the child, with regular follow-up visits to check growth and adjust the dose.
Growth history, bloodwork, and often GH testing and imaging
Daily, or weekly for some children with GH deficiency
Growth, side effects, and lab values tracked over time
When growth is nearly complete; some with GHD continue as adults
For decades, treatment meant a daily injection. That changed in August 2021, when the FDA approved lonapegsomatropin (Skytrofa), the first once-weekly growth hormone for children with GH deficiency, based on a 52-week trial in 161 children that compared it with daily treatment. Two more weekly options followed in 2023: somapacitan (Sogroya) in April for children 2.5 years and older, and somatrogon (Ngenla) in June for children 3 and older. These weekly products are approved for pediatric GH deficiency specifically, and trials showed growth similar to daily injections. Fewer injections may make it easier for families to stay on schedule, which matters because treatment usually lasts years. Along the way, doctors use bone age X-rays to judge how much growing time is left.
How Much Height It Adds Depends on Why a Child Is Short
For children with true GH deficiency, the Pediatric Endocrine Society's 2016 guidelines give their strongest recommendation, backed by high-quality evidence, for using GH to normalize adult height and avoid extreme shortness. In these children, treatment restores growth the body couldn't achieve on its own. For children without a deficiency, the picture is more modest.
The 2008 international consensus on idiopathic short stature put the average adult height gain from GH at 3.5 to 7.5 cm after 4 to 7 years of treatment, and defined a successful first-year response as a gain in height score of more than 0.3 to 0.5 standard deviations. A systematic review of studies that followed children to adult height found an average difference of about 4 cm in randomized trials and about 3 cm in nonrandomized trials. The consensus also noted that predicted adult height can be inaccurate and shouldn't be the sole basis for deciding to treat, and that psychological counseling is worth considering instead of, or alongside, hormone treatment.
Why idiopathic short stature is where experts disagree. The 2016 guidelines advise against routinely treating children with ISS and recommend a shared decision between families and clinicians that weighs the child's physical and psychological burden against treatment risks and benefits, with a reassessment of height and psychosocial impact after 12 months. As the guideline's lead author explained, GH for a true deficiency offers health benefits beyond height, but GH for ISS is solely about height, and not every child with ISS responds. A companion review also noted that height is a poor predictor of how well children adapt psychosocially, and that the hoped-for quality-of-life benefits of treating shortness itself are not well established.
Side Effects and What Doctors Monitor
Post-marketing surveillance of children treated for GH deficiency or ISS has found adverse effects in fewer than 3% of treated children, a favorable safety profile during treatment. The guidelines still call for counseling families about specific risks and monitoring for them.
On cancer risk, the guidelines and a companion review report that GH treatment of GH deficiency or ISS does not increase cancer rates in children without cancer-related risk factors, nor recurrence in those successfully treated for a primary tumor, though children previously treated for cancer, particularly with radiation, appear to have an early, diminishing risk of second tumors. Long-term data after treatment ends are less settled: a French study of adults treated in childhood for isolated GH deficiency, ISS, or being born small for gestational age reported higher all-cause mortality than the general population, but similar studies from other European countries found no effect of GH exposure on mortality. The guidelines recommend that families be told about this uncertainty and the need for ongoing long-term study.
Prescription growth hormone is not something sold over the counter. Growth hormone therapy is a prescription injection that requires a specialist diagnosis, dosing, and monitoring. Dietary supplements are not growth hormone and are not a substitute for it. If you're concerned that your child may have a growth problem, the right first step is a pediatrician visit and accurate growth tracking, as described in our growth hormone deficiency guide.
What This Means For You
The practical takeaway: growth hormone therapy is well established and strongly recommended for children with a true GH deficiency, where it restores normal growth and supports overall health. It's also approved for several other conditions, but for healthy children with idiopathic short stature the average gain is modest, about 1.4 to 3 inches after years of injections, and guidelines favor a careful, shared decision over routine treatment. Side effects during treatment are uncommon but worth knowing. To understand whether a deficiency might be present, start with our guide on when to worry about a child's height.
Frequently Asked Questions
Does growth hormone therapy make kids taller?
In children with GH deficiency, it restores growth and helps normalize adult height, which is why guidelines strongly recommend it. In healthy children with idiopathic short stature, the average adult height gain is about 3.5 to 7.5 cm after 4 to 7 years of treatment, and some children gain little. It isn't used to make children of normal height taller.
Which children are eligible for growth hormone therapy?
The FDA has approved GH for children with GH deficiency, chronic kidney insufficiency, Turner syndrome, Prader-Willi syndrome, being born small for gestational age without catch-up growth, idiopathic short stature, SHOX gene deficiency, and Noonan syndrome. A pediatric endocrinologist decides whether a child qualifies after a full evaluation.
Is growth hormone therapy safe for children?
During treatment, surveillance studies report adverse effects in fewer than 3% of children treated for GH deficiency or idiopathic short stature. Doctors monitor for increased pressure around the brain, hip growth-plate problems, scoliosis progression, and changes in blood sugar. Long-term safety after treatment ends is still being studied, and families should be told about that uncertainty.
Is there a weekly growth hormone shot for kids?
Yes, for children with GH deficiency. The FDA approved lonapegsomatropin (Skytrofa) in 2021, then somapacitan (Sogroya) and somatrogon (Ngenla) in 2023. Trials showed growth similar to daily injections. Daily GH remains the option for the other approved conditions.
Can growth hormone help after growth plates close?
Not for height. GH therapy increases height only while the growth plates are still open, which is why doctors use bone age X-rays to estimate how much growing time remains. Some adults with GH deficiency continue treatment for its metabolic and body composition benefits, but not to grow taller.
